Evaluation of antimicrobial susceptibility for β-lactams against clinical isolates from 51 medical centers in Japan (2008)

Diagnostic Microbiology and Infectious Disease

Volumn 69, Issue 4, 2011, Pages 443-448

  Ishii, Yoshikazu ^a   Ueda, Chihiro ^a   Kouyama, Yuichi ^a   Tateda, Kazuhiro ^a   Yamaguchi, Keizo ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lactams; Drug resistance; Susceptibility

Indexed keywords

CEFEPIME; CEFPIROME; CEFTAZIDIME; IMIPENEM; OXACILLIN; PIPERACILLIN; SULPERAZON;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER FREUNDII; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; JAPAN; KLEBSIELLA; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PSEUDOMONAS; QUALITY CONTROL; SERRATIA; STAPHYLOCOCCUS AUREUS;

BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 79952397752     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2010.10.033     Document Type: Article

References (19)

1. Clinical and Laboratory Standards Institute (CLSI) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- eighth edition, M7-A8 2009, CLSI, Wayne, PA.
2. Clinical and Laboratory Standards Institute (CLSI) (2009b) Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement, vol. M100-S19. Wayne, PA: CLSI.
3. Coque T.M., Baquero F., Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008, 13.
4. Go E.S., Urban C., Burns J., Kreiswirth B., Eisner W., Mariano N., Mosinka-Snipas K., Rahal J.J. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994, 344:1329-1332.
5. IMP. Antimicrob. Agents Chemother. 1998, 42:2006-2011.
6. Ishii Y., Alba J., Kimura S., Shiroto K., Yamaguchi K. Evaluation of antimicrobial activity of β-lactam antibiotics using Etest against clinical isolates from 60 medical centres in Japan. Int. J. Antimicrob. Agents 2005, 25:296-301.
7. Ishii Y., Alba J., Kimura S., Yamaguchi K. Evaluation of antimicrobial activity of β-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004). Diagn. Microbiol. Infect. Dis. 2006, 55:143-148.
8. Ishii Y., Tateda K., Yamaguchi K. Evaluation of antimicrobial susceptibility of β-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn. Microbiol. Infect. Dis. 2008, 60:177-183.
9. Kimura S., Ishii Y., Yamaguchi K. Evaluation of dipicolinic acid for detection of IMP- or VIM- type metallo-β-lactamase-producing Pseudomonas aeruginosa clinical isolates. Diagn. Microbiol. Infect. Dis. 2005, 53:241-244.
10. Lewis M.T., Yamaguchi K., Biedenbach D.J., Jones R.N. In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn. Microbiol. Infect. Dis. 1999, 35:307-315.
11. Maragakis L.L., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 2008, 46:1254-1263.
12. Matagne A., Dubus A., Galleni M., Frere J.M. The β-lactamase cycle: a tale of selective pressure and bacterial ingenuity. Nat. Prod. Rep. 1999, 16:1-19.
13. Matagne A., Lamotte-Brasseur J., Frere J.M. Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem. J. 1998, 330(Pt 2):581-598.
14. Peirano G., Pitout J.D. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents 2010, 35:316-321.
15. Pitout J.D. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010, 70:313-333.
16. Queenan A.M., Bush K. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 2007, 20:440-458.
17. Woodford N., Livermore D.M. Infections caused by Gram-positive bacteria: a review of the global challenge. J. Infect. 2009, 59(Suppl 1):S4-S16.
18. Yamaguchi K., Mathai D., Biedenbach D.J., Lewis M.T., Gales A.C., Jones R.N. Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn. Microbiol. Infect. Dis. 1999, 34:123-134.
19. Yamaguchi K., Ohno A. Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn. Microbiol. Infect. Dis. 2005, 52:135-143.